PSMC1P3

Across TCGA pan-cancer cohorts, PSMC1P3 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PSMC1P3’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where PSMC1P3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PSMC1P3 is over-expressed in tumor, although a few such as PAAD and STAD show the opposite, repressed pattern.

BLCA, LUSC, and PAAD are the cancer types where PSMC1P3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PSMC1P3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	IV	+0.070	.010	4	view →
LUSC	Male	All	+0.028	.019	4	view →
PAAD	Male	All	−0.075	.004	2	view →
STAD	Male	IV	−0.075	.004	2	view →
HNSC	Female	IV	+0.040	.028	2	view →
LUAD	All	All	+0.032	.018	2	view →
THCA	All	IV	−0.037	.029	1	view →
KICH	Female	All	−0.023	.039	1	view →
LIHC	Male	All	+0.008	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PSMC1P3–BLCA

Open the BLCA breakdown →